A single-centre, open-label, randomised, phase II study on the maintenance of ovulation inhibition after intentional application errors during 84 days of treatment with MR-130A-01 contraceptive transdermal patch - MR-130A-01-TD-2002
Latest Information Update: 11 Dec 2025
At a glance
- Drugs Norelgestromin (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Mylan Pharmaceuticals Inc.
Most Recent Events
- 11 Dec 2025 New trial record